NEW YORK --(BUSINESS WIRE)--Nov. 21, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare
NEW YORK --(BUSINESS WIRE)--Nov. 18, 2022-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 15, 2022 , the company granted non-statutory stock options to purchase an
NEW YORK --(BUSINESS WIRE)--Nov. 7, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Jefferies 13 th Annual London Healthcare
Total Revenue Growth of 24 Percent Over Third Quarter of 2021, Driven by Continued Progress Across Drug Discovery Portfolio Full-Year 2022 Revenue Guidance Range Narrowed, with Mix Shifting Toward Drug Discovery Phase 1 Clinical Trial of MALT1 Inhibitor, SGR-1505, Open for Patient Enrollment New
NEW YORK --(BUSINESS WIRE)--Nov. 3, 2022-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor, SGR-2921, will be presented during a poster
NEW YORK --(BUSINESS WIRE)--Oct. 20, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its third quarter 2022 financial results on Thursday, November 3, 2022 , after the financial markets
Highlights Value of Physics-Based Computational Platform to Solve Grand Molecular Design Challenges, Including Application Across 30 Active Drug Discovery Collaborations and Proprietary Programs Outlines Opportunities for Future Innovation and Long-Term Value Creation Announces Drug Discovery
NEW YORK --(BUSINESS WIRE)--Sep. 20, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that the company will host Platform Day in New York City on Thursday, October 6, 2022 , beginning at 10:00
NEW YORK --(BUSINESS WIRE)--Aug. 31, 2022-- Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will participate at Citi’s 17 th Annual BioPharma Conference .
NEW YORK --(BUSINESS WIRE)--Aug. 18, 2022-- Schrödinger , Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the grant of inducement equity awards to the company’s newly appointed chief financial officer,